Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Alvin Luk"'
Autor:
Yuankai Shi, Yongping Song, Yan Qin, Qingyuan Zhang, Xiaohong Han, Xiaonan Hong, Dong Wang, Wei Li, Yang Zhang, Jifeng Feng, Jianmin Yang, Huilai Zhang, Chuan Jin, Yu Yang, Jianda Hu, Zhao Wang, Zhengming Jin, Hang Su, Huaqing Wang, Haiyan Yang, Weijun Fu, Mingzhi Zhang, Xiaohong Zhang, Yun Chen, Xiaoyan Ke, Li Liu, Ding Yu, Guo’an Chen, Xiuli Wang, Jie Jin, Tao Sun, Xin Du, Ying Cheng, Pingyong Yi, Xielan Zhao, Chaoming Ma, Jiancheng Cheng, Katherine Chai, Alvin Luk, Eugene Liu, Xin Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-5 (2020)
Abstract Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise approach to demonstrate biosimi
Externí odkaz:
https://doaj.org/article/9fa40c795d7040e7acb499b265963df7
Autor:
Jiajia Yuan, Jiaxun Zhao, Chong Ye, Long Pang, Xin Zhang, Alvin Luk, Yangyang Du, Kai Yoon Fan, Xiaowen Zhang, Bin Li, Changzheng Chen
Publikováno v:
BioMed Research International. 2023:1-14
Background. LHON is a progressive disease with early disease onset and male predominance, usually causing devastating visual loss to patients. These systematic review and meta-analysis are aimed at summarizing epidemiology, disease onset and progress
Autor:
Alvin Lukita, Melissa Indah Fianty
Publikováno v:
G-Tech, Vol 8, Iss 3 (2024)
In the era of ever-growing globalization, information technology is the main driver of transformation in various sectors of life. Information technology plays an important role in the progress of the tourism sector by offering easy access to informat
Externí odkaz:
https://doaj.org/article/51ba1c27009746ab8abef123d005b56f
Autor:
Xin Du, Tao Sun, Huaqing Wang, Mingzhi Zhang, Xiaohong Han, Yongping Song, Alvin Luk, Xiaohong Zhang, Yan Qin, Dong Wang, Ding Yu, Jie Jin, Zhao Wang, Ying Cheng, Hang Su, Yuankai Shi, Wei Li, Yu Yang, J Feng, Pingyong Yi, Yun Chen, Katherine Chai, Qingyuan Zhang, Li Liu, Huilai Zhang, Xiaonan Hong, Zhengming Jin, Chuan Jin, Yang Zhang, Jianmin Yang, Haiyan Yang, Weijun Fu, Chaoming Ma, Jianda Hu, Xielan Zhao, Eugene Liu, Jiancheng Cheng, Xin Zhang, Xiaoyan Ke, Xiuli Wang, Guo’an Chen
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-5 (2020)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise approach to demonstrate biosimilarity in
Autor:
Alvin Luk, Yongfu Wang, Xiaoxia Zuo, Scott Liu, Xiaofeng Zeng, Baozeng Zhao, Rui Liu, Lan He, Cibo Huang, Weidong Jiang, Pei Hu, Xin Lu, Katherine Chai, Xinjun Guo, Xiao Zhang, Eugene Liu, Zhuoli Zhang, Zhenyu Jiang, Wenting Qiu, Jian Xu, Xin Zhang, Xiumei Liu, Xia Chen
Publikováno v:
SATURDAY, 15 JUNE 2019.
Background Biologic products, such as rituximab and adalimumab, have revolutionized the treatment for chronic inflammatory disorders, providing an option to patients who were non-responsive to conventional systemic therapies. In China, rituximab is o
Autor:
Xin Zhang, Alvin Luk, Jixun Sun, Yanhua Ding, Yiwen Han, Katherine Chai, Weidong Jiang, He Gao, Xinjun Guo, Min Wu, Eugene Liu, Guiling Chen, Tianli Zhang, Scott Liu
Publikováno v:
Poster Presentations.
Background Adalimumab first launched in China in August 2010 with now more than 10 million people have its indications.1, 2 However, the relative high cost of the biologic drug limits the treatment accessibility and reduces the quality of life in pat
Autor:
Yongping Song, Pei Hu, Katherine Chai, Xiaonan Hong, Dong Wang, Xiaohong Han, Xiaofeng Zeng, Kevin Li, Weidong Jiang, Kaka Y. Hong, Yan Qin, Shuiyu Zhao, Alvin Luk, Xin Zhang, Chaoming Ma, Qingyuan Zhang, Scott Liu, Peng Ting, Dan Yao, Yuankai Shi, Eugene Liu, Jiancheng Cheng
Publikováno v:
Blood. 134:2878-2878
Background In February 2019, the National Medicinal Products Administration (NMPA) approved the first China-manufactured rituximab (RTX) biosimilar, HLX01, for the treatment of non-Hodgkin's lymphoma in accordance to the development of biosimilar gui
Autor:
Johannes C.M. Van der Loo, Jerome M. Teitel, Benjamin J. Samelson-Jones, Adam Cuker, Xavier M. Anguela, Marcus E. Carr, Catherine E. McGuinn, Yifeng Chen, Linda B. Couto, Adam Giermasz, Suvankar Majumdar, Katie Wachtel, Jonathan M. Ducore, Stefan Tiefenbacher, Margaret V. Ragni, J. Fraser Wright, Olga Zelenaia, Katherine A. High, Yun Liu, John E.J. Rasko, Daniel Takefman, Lisa M. Sullivan, Angela Winters, Daniel Hui, Alvin Luk, Spencer K. Sullivan, Valder R. Arruda, Lindsey A. George
Publikováno v:
The New England journal of medicine. 377(23)
The prevention of bleeding with adequately sustained levels of clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in the treatment of hemophilia.We infused a si
Autor:
Johnny, Mahlangu, Jerry S, Powell, Margaret V, Ragni, Pratima, Chowdary, Neil C, Josephson, Ingrid, Pabinger, Hideji, Hanabusa, Naresh, Gupta, Roshni, Kulkarni, Patrick, Fogarty, David, Perry, Amy, Shapiro, K John, Pasi, Shashikant, Apte, Ivan, Nestorov, Haiyan, Jiang, Shuanglian, Li, Srividya, Neelakantan, Lynda M, Cristiano, Jaya, Goyal, Jurg M, Sommer, Jennifer A, Dumont, Nigel, Dodd, Karen, Nugent, Gloria, Vigliani, Alvin, Luk, Aoife, Brennan, Glenn F, Pierce, Michael, Guerrera
Publikováno v:
Blood. 123:317-325
This phase 3 pivotal study evaluated the safety, efficacy, and pharmacokinetics of a recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males age
Autor:
Haiyan Jiang, Justin McCue, Jennifer A. Dumont, Margaret V. Ragni, Alvin Luk, Glenn F. Pierce, Jaya Goyal, Doris Quon, Ella Li, Neil C. Josephson, Gregory Cheng, Jurg M. Sommer, Xin Zhang, Jerry S. Powell, Margaret Barbetti, Li Lian
Publikováno v:
Blood. 119:3031-3037
Current factor VIII (FVIII) products display a half-life (t1/2) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single mo